Commercial Due Diligence and Exit Support
HBG supports private equity firms and strategic investors throughout the investment cycle, from pre-acquisition diligence to exit preparation. We validate markets, assess growth potential, and develop objective market studies that build buyer confidence and enhance valuation. Our healthcare and life-sciences expertise drives better outcomes for sponsors and portfolio companies.
CDMO Due Diligence: Pinpointing Opportunity in a Complex Market
The investor signed a letter of intent to acquire a fast-growing contract development and manufacturing organization (CDMO) but lacked sector experience. They needed to validate market attractiveness, customer stickiness, and management strength before closing.
CCM/RPM Diligence: Testing Investment Thesis Under Regulatory Uncertainty
A potential acquisition in chronic care management and remote monitoring showed promise but came with reimbursement and policy risk. The investor needed clarity on sustainability and growth levers before bidding.
Temperature-Controlled Packaging: Positioning for a Successful Exit
Evolving environmental standards and pandemic-driven vaccine transport created volatility in the temperature-controlled packaging market. The company needed an independent market study to educate buyers and strengthen its sale narrative.
Temperature-Controlled Packaging: From Diligence Insight to Market Expansion Strategy
When a private-equity investor considered acquiring an innovative supplier of reusable temperature-controlled packaging (TCP), they turned to HBG for commercial diligence. The deal team needed to validate market growth, competitive positioning, and regulatory and pharmaceutical-industry risks before proceeding.